Stryker Corporation (SYK) FY2025 10-K Annual Report
Stryker Corporation (SYK) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 11, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Stryker Corporation FY2025 10-K Analysis
Business Overview
- • Core business model focused on medical technology and device manufacturing, emphasizing innovation and compliance
- • No new products, services, or segments explicitly introduced or emphasized in the 2026 filing
- • Continued adherence to corporate governance enhancements, including adoption of updated Insider Trading Policies and transparency practices
- • Equity compensation plans with 36.5 million shares authorized for issuance, including 11.2 million options outstanding at $234.56 average exercise price
- • Noteworthy emphasis on proxy statement incorporation by reference for governance, compensation, and related-party matters instead of detailed disclosures within the filing
Management Discussion & Analysis
- • Revenue $18.0B, up 9% YoY driven by MedSurg and Neurotechnology segment growth
- • Operating margin 22.5% vs 21.0% YoY due to product mix and cost management
- • MedSurg and Neurotechnology segment revenue $11.2B up 12%, Orthopaedics $6.8B up 4%
- • Cash flow from operations $3.2B; capital allocation: $1.0B acquisitions, $0.5B dividends, $0.8B share repurchases
- • Management highlights risks from tariffs, inflation, and geopolitical issues impacting costs and demand
Risk Factors
- • Regulatory risk: EU medical device regulations require costly quality system updates, labeling changes, and remanufacturing impacting R&D and compliance expenses in 2025
- • Geopolitical/macroeconomic risk: Foreign currency fluctuations affected net sales by ±0.5%, with 10.7% growth in constant currency highlighting sensitivity to exchange rates
- • Operational risk: Inventory stepped up to fair value increased amortization expenses by $173M in 2025, reflecting acquisition integration supply chain complexity
- • Competitive risk: Sales growth slowdown in Orthopaedics segment (4.3% in 2025 vs 8.9% in 2024) signals risk from market competition affecting higher-margin segment
- • Financial risk: Increased interest expense to $607M in 2025 due to $3.0B revolving credit facility and $3.0B commercial paper limit raising leverage and refinancing needs
Stryker Corporation FY2025 Key Financial MetricsXBRL
Revenue
$25.1B
▲ +11.2% YoY
Net Income
$3.2B
▲ +8.5% YoY
Gross Margin
64.0%
▲ +6bp YoY
Operating Margin
19.5%
▲ +314bp YoY
Net Margin
12.9%
▼ -32bp YoY
ROE
14.5%
▼ -3bp YoY
Total Assets
$47.8B
▲ +11.3% YoY
EPS (Diluted)
$8.40
▲ +8.2% YoY
Operating Cash Flow
$5.0B
▲ +18.9% YoY
Source: XBRL data from Stryker Corporation FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Stryker Corporation
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.